Xarelto Faces Approval, Labeling Obstacles Even After Cmte. Endorsement
Executive Summary
Bayer and Johnson & Johnson may have won the battle in securing an FDA advisory committee endorsement of Xarelto (rivaroxaban) for atrial fibrillation, but they may well lose the war of the novel anticoagulants given the panel’s unfavorable labeling recommendations if the oral Factor Xa inhibitor is approved.
You may also be interested in...
ROCKET AF’s Design Causes Headaches For Xarelto Sponsors
Key design elements of the Xarelto pivotal trial in atrial fibrillation have come back to haunt sponsors Bayer and Johnson & Johnson during the course of the rivaroxaban NDA review.
Xarelto Review Puts FDA’s Comparative Effectiveness Stance To The Test
Pharmaceutical sponsors across therapeutic categories may have breathed a sigh of relief when FDA’s Cardiovascular and Renal Drugs Advisory Committee said that Bayer/Johnson & Johnson’s Xarelto (rivaroxaban) need not show it is “as effective” as Boehringer Ingelheim GmbH’s anticoagulant Pradaxa (dabigatran) in atrial fibrillation patients.
ROCKET AF’s Design Causes Headaches For Xarelto Sponsors
Key design elements of the Xarelto pivotal trial in atrial fibrillation have come back to haunt sponsors Bayer and Johnson & Johnson during the course of the rivaroxaban NDA review.